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Drug-induced liver injury (DILI) is a complication of treatment with anti-tuberculosis 
(TB) drugs, especially in isoniazid-containing regimens. To investigate genetic risk 
factors, we performed a genome-wide association study (GWAS) involving anti-TB 
DILI cases (55 Indian, 70 European) and controls (1199 Indian, 10397 European). Most 
cases were treated with a standard anti-TB drug regimen; all received isoniazid. We 
imputed single nucleotide polymorphism and HLA genotypes and performed trans-
ethnic meta-analysis on GWAS and candidate gene genotypes. GWAS found one 
significant association (rs117491755) in Europeans only. For HLA, HLA-B*52:01 was 
significant (meta-analysis odds ratio (OR) 2.67; 95%CI 1.63-4.37; P=9.4x10-5). For N-
acetyltransferase 2 (NAT2), NAT2*5 frequency was lower in cases (OR 0.69; 95%CI  
0.57-0.83, P=0.01). NAT2*6 and NAT2*7 were more common, with homozygotes for 
NAT2*6 and/or NAT2*7 enriched among cases (OR 1.89; 95%CI 0.84-4.22; P=0.004). 
We conclude HLA genotype makes a small contribution to TB drug-related DILI and 
that the NAT2 contribution is complex, but consistent with previous reports when 
differences in the metabolic effect of NAT2*5 compared with those of NAT2*6 and 









Up to 20% of patients receiving isoniazid either as mono or combination therapy for 
tuberculosis (TB) may develop transient asymptomatic elevation of liver enzymes but 
this elevation usually resolves without drug discontinuation.1, 2 In a recent large 
prospective cohort study based in China, 5.4% of patients on anti-TB combination 
therapy developed drug-induced liver injury (DILI)3 as defined by the International 
DILI Expert Working Group.4 In 16% of these cases, DILI was accompanied by other 
symptoms of hepatotoxicity including jaundice and 5.3% developed acute liver failure.3 
Recurrence of DILI upon retreatment (called positive rechallenge) has been reported to 
occur in approximately 9%-25% with at least one of the anti-TB drugs.1, 2, 5, 6 The 
incidence of DILI when isoniazid (INH) is combined with rifampicin appears higher 
than for INH alone, with addition of pyrazinamide increasing the risk further.7 
A number of drug-specific and host related factors influence the susceptibility of a 
patient to DILI with anti-tuberculosis drugs.8  Potential mechanisms related to INH 
DILI have been the most widely investigated. Acetylhydrazine is generally considered 
to be a key INH metabolite contributing to INH-induced DILI and is produced by N-
acetyltransferase 2 (NAT2). It can undergo further metabolism by cytochrome P450 to 
a toxic metabolite or by NAT2 to the less toxic diacetylhydrazine. It has been suggested 
that fast acetylators (those with NAT2 activity within the normal range) will form 
diacetylhydrazine efficiently and therefore levels of both acetylhydrazine and toxic 
P450 metabolites will be low.9 It has also been proposed that slow acetylators who lack 
NAT2 activity may form higher concentrations of the toxic metabolite hydrazine by 
cleavage of the amide bond on INH to form isonicotinic acid.10 There are also data to 
suggest formation of a reactive metabolite directly from INH oxidation which may 
contribute to liver toxicity through the formation of protein adducts11 inducing an 
inappropriate immune response.12 
Because of the important contribution by acetylation to INH metabolism and the 
existence of common loss of function polymorphisms in NAT2, the gene encoding the 
acetylation enzyme, there have been a large number of studies examining these variants 
as DILI risk factors. At least four different meta-analyses including large numbers of 
cases have concluded that slow acetylators have an increased risk of TB drug DILI with  
an overall odds ratio (OR) varying from 1.59 to 6.42, although the risk varied depending 
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on the  precise genotypic definition of slow acetylation and the population studied.13-16 
Although many of these studies involved a limited number of patients experiencing 
only mild liver injury, the NAT2 association has also been observed in a study involving 
moderate to severe DILI cases only.17 A clinical trial based in Japan with differential 
dosing with INH on the basis of NAT2 genotype found a lower incidence of DILI when 
slow acetylators were given a lower dosing regimen.18  A genome-wide association 
study (GWAS) involving patients from Thailand recently described a genome-wide 
significant signal for NAT2, suggesting a stronger risk for DILI development in those 
positive for slow acetylator alleles in line with many of the earlier candidate gene 
studies.19 However, two GWAS which included small numbers of European cases with 
anti-TB DILI did not find any genome-wide significant association with the NAT2 slow 
acetylator genotype.20, 21 
In addition to NAT2 variants, other candidate genetic risk factors for anti-TB DILI have 
also been investigated, with reports suggesting that genotypes for genes relevant to anti-
TB drug disposition and oxidative stress such as CYP2E1,22 SOD2,23 GST isoforms,23 
carboxyesterase (CES) isoforms24 and PXR (NR1I2)25 may modulate risk. Human 
leukocyte antigen (HLA) genotype is a strong risk factor for a number of forms of 
DILI21 and it has been suggested that HLA class II genotype is relevant to risk of DILI 
due to anti-TB drugs in an Indian population.26 However, further studies using either 
candidate gene or genome-wide approaches have failed to confirm a role for HLA 
genotype in susceptibility to anti-TB drug-related DILI in Europeans.20, 21, 27 A recent 
study of DILI due to anti-TB drugs in an Ethiopian population who were also HIV-
positive and receiving anti-HIV treatment found an interesting association with the 
class I HLA B*57 alleles,28 but this form of DILI showed distinct phenotypic 
differences from that normally associated with anti-TB drugs. A non-HLA 
immunogenetic risk factor for DILI generally in the gene PTPN22 has also been 
identified recently but its relevance to anti-TB drug related DILI has not been 
investigated in detail to date.29 
The aims of the current study were to perform a GWAS together with additional 
candidate gene studies on a newly recruited group of Indian patients with moderate to 
severe anti-TB drug DILI  and on an enlarged European cohort which includes some 




This study combined in a trans-ethnic meta-analysis framework results from GWAS 
conducted separately in subjects with European and Indian ancestry. The study was 
conducted according to the Declaration of Helsinki (Hong Kong Amendment) and 
Good Clinical Practice (European guidelines). All participants provided written 
informed consent and each study was approved by the appropriate local (Department 
of Gastroenterology, St John’s Medical College Hospital, Bangalore, India and 
Christian Medical College, Vellore, India), national or institutional ethical review 
boards as reported previously.21, 29 
Indian cohort 
Patients (n=55) who developed DILI after exposure to INH in combination with 
rifampicin, pyrazinamide and ethambutol (all 4 drugs for first 2 months and INH and 
rifampicin for further 4 months), 105 patients treated with these drugs without DILI 
development and 104 healthy South Indian adults of mixed ancestries  were enrolled 
from Aug 2009 to Feb 2014 at St John’s Medical College, Bengaluru and Christian 
Medical College, Vellore, South India. Roussel Uclaf Causality Assessment Method 
(RUCAM) was used for case adjudication as described previously.4 To further increase 
study power, we added to the control set a total of 990 ethnically matched samples 
comprising 356 from 1000G project and 634 controls of Indian descent from Charles 
Bronfman Institute for Personalized Medicine BioMe BioBank (phs000925.v1.p1) 
identified by principal component analysis (see Supplementary Materials).  
European cohort 
We analyzed 70 European ancestry DILI cases exposed at least to INH alone or in 
combination with one or more of rifampicin, pyrazinamide and ethambutol, collected 
by the DILIGEN, iDILIC and DILIN consortia. Of these cases, 43 were treated with 
INH alone as standard TB prophylaxis and 27 had been treated with any combination 
of INH and one or more additional anti-TB drugs with 11 of those exposed to all four 
drugs. These cases all form part of a large cohort of DILI cases previously analyzed by 
GWAS,29 with some also included in earlier studies as summarised in Table S1. A 
subgroup of 12 UK cases (DILIGEN study) had been included in an earlier study 
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involving direct NAT2 genotyping only17 but subsequently also underwent genome-
wide genotyping.20 European ancestry controls (n=10397) were used.29  
Clinical characterisation of DILI  
Criteria used for case definition, categorisation of DILI pattern as well as grading of 
severity of DILI were harmonised across all cohorts using previous guidelines.4 
Causality assessment was done by RUCAM score for the DILIGEN and iDILIC cohorts 
and by both structured expert opinion and RUCAM score for the DILIN cohort, as 
previously reported.20, 21   
DNA preparation and genotyping 
For the Indian cases and controls, DNA was isolated from whole blood samples using 
the standard phenol-chloroform method. DNA samples were genotyped in one batch 
using the Illumina Human Core Exome-24 BeadChip by Department of Molecular 
Genetics, Madras Diabetes Research Foundation, India. DNA isolation and genotyping 
of European cases from the DILIGEN, iDILIC and DILIN studies was as described 
previously.20, 21  
Population structure and imputation 
Quality control (QC) checks on the initial genotype data were performed as described 
previously.29 To assess the extent of population structure of the study cohorts, and 
derive eigenvectors to account for confounding, we applied principal component 
analysis on each cohort separately, using the smartPCA program from the 
EIGENSTRAT package (version 3.0)30 on the overlapping single nucleotide 
polymorphisms (SNPs) (minor allele frequency, MAF>0.01) across the range of 
genotyping arrays used for typing cases and controls. We used 1000 Genome Project 
samples as the reference panel to select cases and controls of Caucasian and South 
Indian ancestries. SNP imputation was performed in batches dividing the samples 
according to ethnicity and genotyping platforms. For each batch imputation was carried 
out using Michigan Imputation Server as described previously.29 
GWAS analysis and meta-analysis 
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We tested for association of each SNP with DILI, separately in Indian and European 
GWAS, in a logistic regression framework, under an additive genetic model, with 
adjustment for the principal components from smartPCA to account for population 
structure using PLINK v 1.07.31 No other additional covariates were included in the 
model since we did not have clinical information for controls. Association summary 
statistics from the two cohorts were combined using effective sample size weighted Z-
score fixed-effects meta-analysis, implemented in METAL.32  Allelic odds ratios (ORs) 
across the two cohorts were obtained through inverse-variance weighting of effect 
sizes, with heterogeneity assessed with Cochran’s Q statistic,33 implemented in 
METAL. We reported only those SNPs that attained, in addition to genome-wide 
significance, nominal evidence of association (P<0.05) with the same direction of effect 
on DILI in both GWAS phases (internal validation). Genome-wide significance with 
clinical outcomes was defined using a common threshold of P<5x10-8. Since the 
phenotypes studied are rare, the number of cases analyzed was limited. All detailed 
analyses and Manhattan plots were produced with R (version 3.0.2, The R Project for 
Statistical Computing, http://www.r-project.org). Regional plots were drawn by 
LocusZoom as described previously.21 
HLA analysis 
For each cohort, HLA alleles were inferred using HIBAG34 using the reference 
predictor panels specific for the genotyping chip and ancestry provided in the software 
webpage. To impute Indian samples we used the provided Asian reference data.34 In 
total, we imputed 217 HLA alleles in the overall European cohort and 192 in the Indian 
cohort. We set the MHC-region-wide significance p-value threshold for the HLA allele 
association to 2.5x10-4 to correct for multiple testing (Bonferroni correction for 200 
predicted HLA alleles). Association test for each HLA allele and meta-analysis were 
carried out as reported above. Haplotype analysis was performed by Plink 1.07 
including the most significantly associated HLA alleles.  
NAT2 genotypes 
We predicted NAT2 alleles using genotypes for rs1801280, rs1799930 and rs1799931 
from the GWAS (NAT*5, *6 and *7 alleles respectively) by haplo.stats (https://cran.r-
project.org/web/packages/haplo.stats/index.html) and extracted the best haplotype 
predictions based on posterior probability.  We tested for association between DILI and 
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allele by logistic regression with adjustment for the principal components in Plink. 
NAT2 genotypes were recorded and samples were divided into different acetylator 
status groups as originally proposed35 and refined more recently:36 (a) rapid (*4/*4); (b) 
intermediate (*4/*5,*4/*6,*4/*7); (c) slow (*5/*5,*5/*6,*5/*7); (d) ultraslow 
(*6/*6,*6/*7,*7/*7). We then tested for association between DILI and acetylator status 
groups and genotypes in a multivariate regression model including principal 
components axes and acetylator status groups or genotypes as binomial variable or as 
categorical variable having 44 genotype or rapid/intermediate as baseline groups. The 
meta-analysis p-value was calculated using METAL with the default approach that 
combines p-value and direction of effect, weighted according to sample size.32 
Significance was defined using a Bonferroni threshold of P < 0.01 considering 4 
comparisons. 
Candidate gene analysis 
For analysis of additional candidate genes, we selected four genes previously proposed 
to have a role in the pathogenesis of INH-related DILI, including CYP2E1, CES2, 
CES1 and PXR/NR1I2. We extracted all variants belonging to each gene from 
GnomAD (https://gnomad.broadinstitute.org/). We performed an association analysis 
by Plink 1.07.31 Significance was defined using a Bonferroni threshold of P< 0.003 




Cases and controls 
Clinical characteristics of the 55 DILI cases from India and 70 European cases are 
summarised in Table 1.  The total Indian DILI cohort was enriched in cases with severe 
liver injury with 22% of all patients progressing to acute liver failure, transplant or 
death. The majority of the European DILI cases met the definition of moderate to severe 
DILI used in our previous European DILI studies.21 Nine European patients (13%) 
suffered liver failure, underwent liver transplant or died (Table 1).  
As controls for the Indian cases, we used 1199 ethnically matched individuals (105 
patients treated for TB by similar regimens who did not develop DILI and 104 healthy 
adults recruited for this study, 356 from 1000G project phase 3 dataset and 634 from 
BioMe dataset (Figure S1)). As European controls, we used 10397 ethnically matched 
individuals (Figure S2). 
A schematic summary of the overall study is provided in Figure 1. 
GWAS analysis 
The case-control GWAS in the European cohort showed one marker that passed the 
significance threshold (rs117491755, OR=4.37, 95%CI [2.702-7.061], P=1.8x10-9; 
AFcases = 0.143; AFcontrols = 0.037) (Figure 2A). rs117491755 is an intronic SNP in 
ASTN2. For the Indian cohort, there were no genome-wide significant associations 
between DILI and imputed or genotyped variants and rs117491755 did not pass QC 
checks in the imputed dataset (Figure 2B). Trans-ethnic meta-analysis between the two 
ethnic groups analysed 4,900,532 shared markers between the two cohorts. None of the 
variants in the meta analysis reached genome-wide significance (Figure 2C). 
HLA analysis 
In the European cohort, we identified two major histocompatibility complex (MHC) 
significant signals, HLA-C*12:02  (OR=6.43; 95%CI [2.53-16.37] ; P = 9.4x10-5, Table 
2 and Table S1) and HLA-B*52:01 (OR=6.39; 95%CI [2.25-16.29] ; P = 1.0x10-4, Table 
2). All carriers presented with both alleles. The B*52:01-C*12:02 haplotype conferred 
a significant increase in DILI risk of almost 7-fold (P = 7.8x10-5, Table S2), although 
the overall haplotype frequency is low even in the cases. The alleles were mainly 
 12 
associated with DILI cases due to drug combinations compared with INH alone (Table 
S3). Slightly different HLA results were observed for Indian cases. These cases showed 
an enrichment in class II HLA risk alleles with HLA-DQA1*03:01 (OR= 2.60, 
95%CI[1.54-4.38]; P = 0.0003, Table 2) as the most significantly associated allele, 
though not passing the MHC multiple correction threshold. Indian cases also showed a 
nominal enrichment of HLA-B*52:01 and HLA-C*12:02 alleles compared with 
controls (Table S2). In line with the data from Europeans, the haplotype conferred a 
1.45 fold increase in risk of DILI (P = 0.04, Tables 2 and S2). In meta-analysis HLA-
B*52:01 showed a MHC-significant association (OR=2.67; 95%CI 1.63-4.37; P = 
9.4x10-5, Table 3).  
Candidate gene analysis 
NAT2 genotypes 
The frequency of the NAT2 alleles in both cohorts are summarised in Table 3. NAT2 
allele frequencies for our cohorts were similar to frequencies  reported previously with 
Indians showing a high frequency of the NAT2*6 allele in the control group compared 
to Europeans whereas in the European controls NAT2*5 was the most common allele.37 
We tested association between each allele and DILI correcting for population 
stratification (Table 4). We found that NAT2*5 was the most underrepresented NAT2 
allele in both European and Indian cases, passing the Bonferroni correction for the 
number of the predicted NAT2 alleles (PMeta-analysis = 0.01, Table 4). NAT2*6 was 
significantly enriched in Indian cases (P = 0.01). Severe Indian cases (n = 12) showed 
a slightly higher frequency for NAT2*6 (AF = 0.54) and lower frequency of NAT2*5  
(AF = 0.11) compared to the overall cases, with NAT2*5 statistically significant as a 
protective factor compared to controls (OR = 0.30; 95%CI 0.08 - 0.94; P = 0.05). 
Among Europeans, INH alone cases (n = 43) showed a significantly decreased 
frequency for NAT2*5 (AF = 0.34, P = 0.04) (Table 4). The group of European severe 
cases (n=9) was too small to detect significant trends. 
We then assigned NAT2 genotypes for each individual and classified them in four 
acetylator status groups. We evaluated if there was an enrichment of any of the groups 
in our cases compared to controls. We found that ultraslow acetylators (those carrying 
homozygous or compound heterozygous genotypes for NAT2*6 and NAT2*7) were 
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significantly enriched in cases compared with controls (PMeta-analysis = 0.004, Table 5). 
This enrichment was not significant in a multivariable regression model for which we 
combined rapid and intermediate acetylators as the baseline group (PEuropean = 0.08, and 
PIndian = 0.1). Examining the enrichment of single genotype groups, the only set  
significantly associated with DILI by meta-analysis was NAT2*6/NAT2*7 (P = 0.002) 
which was also significant in Europeans alone (P = 0.01, Table S4).  
Other candidate gene analysis  
We extracted variants located in selected candidate genes relevant to INH metabolism 
(CYP2E1, CES2, CES1 and PXR/NR1I2) from GnomAD 
(https://gnomad.broadinstitute.org) for a total of 16 imputed/genotyped SNPs in 
European (CYP2E1 n = 9; CES2 n = 2; CES1 n = 0; PXR/NR1I2 n = 5) 14 in Indians 
(CYP2E1 n = 5; CES2  n = 3; CES1 n = 4; PXR/NR1I2 n = 2). Since imputation is 
based on ethnicities and genotyping platforms, the SNPs available for analysis in the 
candidate genes were different for the two groups.  No variants were significantly 
associated with DILI (Table S5).   
Frequency of rs2476601 in PTPN22 that has been previously associated with DILI due 
to several different drugs,29 was not increased in European DILI cases (AFcases 0.10; P 
= 0.40) and INH alone cases (AFcases 0.12; P = 0.15) but was marginally increased in 





Despite a relatively large number of published studies, the genetic basis for 
susceptibility to DILI due to anti-TB drugs including INH remains poorly understood 
compared with DILI caused by certain other drugs such as flucloxacillin and 
amoxicillin-clavulanate. There are a number of reasons for this including: (a) the 
complexity of the phenotype (both mild and more serious cases of DILI due to anti-TB 
drugs are common); (b) the fact that the standard treatment typically involves a 
combination of four different drugs; (c) both TB as a disease and DILI induced by anti-
TB drug treatment are more common in developing countries where relevant genetic 
polymorphisms may show differing frequencies than in Europeans where DILI has been 
studied more extensively, making worldwide comparisons difficult. Furthermore, in 
some countries where concomitant infection with TB and HIV is more common, 
assessment of causality as to whether the DILI is due to the anti-HIV drugs, anti-TB 
drugs, or both, is often unclear. 
Similar to the findings in two earlier GWAS involving Europeans,20, 21 we failed to 
detect genome-wide significance when we undertook a GWAS in the Indian population. 
This is in contrast to the recent GWAS performed on a Thai population, where genome-
wide significance was seen for NAT2,19 but is more consistent with a separate GWAS 
performed in Ethiopians which also failed to observe genome-wide significant 
signals,38 although the Ethiopian patients were also undergoing HIV treatments that can 
cause DILI. In our enlarged European population which includes the previously studied 
cases 20, 21 as well as  8  new cases,29 we did see one genome-wide significant signal in 
an intronic SNP in ASTN2. This gene product appears to affect synaptic strength by 
trafficking and degradation of surface proteins.39 The relevance to DILI is not 
immediately clear and this signal was not seen in the Indian population. Without a 
positive replication, we have to consider this signal as either a false-positive or putative, 
until further patients have been studied. 
While the current study and several previous reports failed to detect strong HLA 
associations, we found some evidence that a rare HLA-C*12:02 -B*52:01 haplotype, 
which has been recently reported to be a risk factor for Crohn's disease in Asians, might 
contribute to risk of anti-TB drug DILI in some individuals.40 The effect of the 
haplotype seems to be consistent across both cohorts and the association passes the 
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Bonferroni correction based on the number of imputed alleles. Meta-analysis showed 
that the effect of the B*52:01 allele alone was more significant than for C*12:02. The 
number of cases positive for the risk allele was low but importantly both cohorts 
showed this association and that there is an already reported association for the 
haplotype with an autoimmune disease.40 In view of the small number of cases positive 
for the "at risk" haplotype and the absence of a signal in the INH only cases, it is 
possible that the HLA signal may reflect DILI induced by one of the other anti-TB 
drugs, possibly pyrazinamide. 
A previous HLA class II typing study in an Indian population reported that absence  of  
HLA-DQA1*01:02,  and presence of HLA-DQB1*02:01 were risk factors for DILI due 
to anti-TB drugs.26 However, in the current study the most significant findings for class 
II were increased frequencies of HLA-DQA1*01:03 and HLA-DQA1*03:01, although 
we did not observe this in Europeans. We also saw no association with B*57 alleles but 
as discussed previously, we consider that this particular association may relate to a 
combination of anti-HIV and anti-TB drug treatment28 which we would not expect to 
see confirmed in the current study.  
The PTPN22 variant rs2476601 has recently been found to be an additional risk factor 
for some forms of DILI showing HLA associations.29 We therefore also evaluated the 
role of this variant in our patients with anti-TB-related DILI, but did not find a 
significant association. However, the allele frequency of rs2476601 in South Asian 
populations is consistently lower compared to European populations (1% vs 10%, as 
reported in GnomAD) so our ability to detect any association was also limited. 
In view of very limited genome-wide or near genome-wide significant signals in the 
GWAS, we proceeded with additional candidate gene analysis using the GWAS data, 
focussing on NAT2, given the extensive literature which has demonstrated that NAT2 
genotype and phenotype is a risk factor for INH-induced DILI. Three meta analyses on 
NAT2 as a DILI risk factor which include studies published up to 2017  together with 
two recent large studies appear to be the most informative to use for comparison with 
the current study.13-15, 19, 41  In general, most previous studies on NAT2 genotype as a 
risk factor have examined all slow acetylators in comparison with either homozygous 
wild-types (who are often now classified as the fast acetylator group without inclusion 
of heterozygotes) or both homozygous wild-types and those heterozygous for one 
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variant allele only (the traditional fast acetylator group). In some studies, heterozygotes 
are designated as intermediate acetylators and were analysed separately.  
There is however increasing data available which indicates that NAT2*5, which is 
common in Europeans, South Asians and Africans, but not in East Asians, is not a true 
"slow acetylator" allele with the gene product retaining some enzyme activity while the 
enzymes encoded by both NAT2*6 and NAT2*7 are associated with no activity.36, 42, 43 
In line with this, a recent study of South African Zulus examined levels of INH and 
certain metabolites in relation to NAT2 genotype in patients undergoing treatment with 
INH and did not find a significant difference in drug and metabolite levels when 
comparing NAT2*5 homozygotes or heterozygotes with those homozygous for two 
rapid acetylator alleles. NAT2*6 and NAT2*7 alleles were not detected in this 
population.44 One relatively small study of phenotype-genotype relationships in healthy 
Swedish volunteers used INH for phenotype determination and reported a higher 
metabolic ratio for NAT2*5 homozygotes compared with NAT2*6 homozygotes.45 
The NAT2 genotype distribution among the DILI cases in the current study indicates a 
protective effect for the NAT2*5 allele with NAT2*4 "neutral" whereas an increased 
risk was seen for NAT2*6 with the combined "ultraslow" group also showing a 
statistically significant increased risk. This is in agreement with a meta-analysis 
reporting an increased risk for NAT2*6 and NAT2*7.43 A recent study performed in 
Singapore also suggests that the risk for INH-related DILI is from NAT2*6 and *7 
only.41 This could also explain the recent genome-wide significance reported for NAT2 
variants in Thailand 19 since NAT2*5 is rarely seen in this East Asian population. One 
of the earliest reports on NAT2 genotype as a risk factor for INH-related DILI was 
performed in Taiwan.46 This study found a small number of individuals positive for 
NAT2*5 but hepatotoxicity was seen almost entirely in those carrying at least one 
NAT2*6 or NAT2*7 allele. The biological basis for this complex association with NAT2 
genotype is not completely clear but *6 and *7 carriers may be at increased risk of 
toxicity due to higher levels of the parent drug undergoing metabolism by alternative 
routes to toxic intermediates such as hydrazine or possibly by accumulation of the 
acetylhydrazine metabolite which also may be converted to hydrazine.9 INH-related 
DILI was  reported to be more common among East Asians compared with white 
Europeans and African-Americans in early population studies.47, 48 This could reflect 
the higher frequency of the NAT2*6 and NAT2*7 alleles in these populations46 
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compared with those reported for Europeans,45 despite the overall average higher 
acetylation activity seen in East Asians. It also remains possible that the recent GWAS 
findings reported for a Thai population19 showing significance for NAT2 are not directly 
comparable to the current study as the liver enzyme elevation thresholds for 
participation in that study were considerably lower than in the current study.  
We also studied four additional genes potentially relevant to INH disposition in detail 
in both cohorts to see if any evidence for trends towards genome-wide significance 
could be detected. These were chosen on the basis of direct relevance to the INH 
metabolic pathway9 and either encode enzymes (CYP2E1, CES1 and CES2) or 
transcription regulators with a role in regulation of gene expression (PXR/NR1I2 which 
regulates CES expression). Our findings were entirely negative. We believe this is not 
too surprising and is generally consistent with reports in the existing literature of no 
significance or small effects.24, 49 Larger studies might enable the detection of smaller 
effects than was feasible in the current study. 
A limitation of this study and most others on DILI due to anti-TB drugs is that in 
addition to INH, the other drugs used in treatment, especially pyrazinamide, can also 
cause DILI. All cases in the Indian cohort were related to combination anti-TB drug 
therapy while a significant proportion of DILI cases in the European cohort were 
attributable to INH monotherapy so the two cohorts are not identical in terms of drug 
treatment. This is an important limitation but the results obtained for the two cohorts, 
especially for NAT2 genotype and to some extent for HLA genotype, are still 
comparable. Alternative regimens not involving INH show slightly lower incidence of 
hepatotoxicity but DILI may still occur50 and although it may be possible to determine 
which drug causes DILI in a particular patient, this requires a series of individual drug 
rechallenges which is difficult to perform and was not feasible in the current study. 
In conclusion, we have obtained some evidence that certain NAT2 alleles increase the 
risk of DILI in patients receiving INH-containing anti-TB drug regimens. The two 
cohorts we studied were large compared with most previous studies with a well-defined 
phenotype but were still small compared with GWAS on more common diseases where 
relatively small but significant effects can be detected by use of very large cohorts. 
There is a need for additional studies involving either larger cases numbers or additional 
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meta analyses to better understand the underlying risk factors for DILI due to INH and 
other anti-TB drugs.  
 
STUDY HIGHLIGHTS 
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? 
Anti-tuberculosis (TB) drugs including isoniazid are a common cause of drug-induced 
liver injury (DILI). Previous reports suggest NAT2 genotype and some HLA alleles are 
risk factors but not all studies agree on this. 
WHAT QUESTION DID THIS STUDY ADDRESS? 
We aimed to identify novel genetic risk factors for DILI due to anti-TB drugs including 
isoniazid in European and Indian cases and consolidate understanding on relevance of 
HLA and NAT2 genotypes to risk of DILI. 
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? 
The study provides further support for  NAT2*6 and NAT2*7 variants of NAT2 as risk 
factors for development of anti-TB drug-related DILI and for NAT2*5 being protective. 
There may also be increased  risk in those carrying the HLA-B*52:01 allele.  
HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY OR 
TRANSLATIONAL SCIENCE? 
The study provides further support for NAT2 and HLA contributions to risk of DILI 
from TB drugs, adding to knowledge that may lead to genetic tests capable of 
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Clinical characteristics   
Number of cases 55 70 
Gender (F/M) 28/27 37/33 
Age (years) (Mean ,SD) 40 (16.1) 55.1 (13.9) 
Time to onset from first drug exposure (days) (Mean, SD) 46.8 (55.1) 55.2 (45.8) 
Pattern of DILI   
Cholestatic  18% (10) 5.7% (4) 
Hepatocellular 59% (32) 77.1% (54) 
Mixed 22% (12) 10.0% (7) 
Unknown 1% (1) 7.1% (5) 
Causal drug   
Isoniazid and rifampicin (IR)  1.4% (1) 
Isoniazid, rifampicin, pyrazinamide (IRP)  21.4% (15) 
Isoniazid, rifampicin, pyrazinamide and ethambutol 
(IRPE) 
100% (55) 15.7% (11) 
Isoniazid (I)  
61.43% 
(43) 
Severity   
Mild 0 11% (8) 
Moderate 78% (43) 73% (51) 
Severe/Fatal 22% (12) 13% (9) 
Not Reported 0 3% (2) 
Causality Score (CIOMS/RUCAM)   
3-5 (possible) 6% (3) 18% (13) 
6-8 (probable) 60% (33) 60% (42) 
>8 (highly probable) 34% (19) 21% (15) 
Genotyping platform   
1M Illumina Duo (%,N)  39% (27) 
Infinium Core Exome (%,N) 100% (55) 50% (35) 





Table 2 The most significant HLA associations for European and Indian cohorts  
 
 






European associations           
  
HLA-C*12:02 6.43 2.526-16.37 0.00009 0.04 0.006 0.009 
HLA-B*52:01 6.40 2.511-16.29 0.0001 0.04 0.007 0.009 
HLA-DRB1*15:02 6.36 2.489-16.25 0.0001 0.04 0.006 0.007 
  
 
    
Indian associations             
HLA-DQA1*03:01 2.60 1.53-4.38 0.00035 0.15 0.06 0.09 
HLA-DPB1*01:01 3.24 1.58-6.61 0.0013 0.09 0.02 0.02 
HLA-DPB1*03:01 3.60 1.58-8.19 0.0023 0.07 0.02 0.05 
HLA-DRB1*04:06 8.48 2.02-35.52 0.00346 0.02 0.00 0.00 
HLA-DQA1*01:03 1.85 1.21-2.84 0.0047 0.27 0.14 0.14 
 
OR= Odds ratio of a multivariate regression model correcting for population stratification; 95%CI= confident interval of the Odd Ratio; AF 
Cases=allele frequency in cases; AF Controls =allele frequency in controls ; AF reference dataset = allele frequency calculated  based on the 
















OR= Odds ratio of a multivariate regression model correcting for population stratification; 95%CI= confidence interval of the Odds Ratio; AF 
Cases=allele frequency in cases; AF Controls = allele frequency in controls; AF reference dataset = allele frequency calculated  based on the 
number of carriers estimated from all cohorts belonging to a particular geographic region reported in www.allelefrequencies.net; PV=multinomial 
p value; PVm =meta-analysis pvalue; HetPV= Heterogeneity p value 
  
  
Marker Direction of effect OR 95%CI PVm HetPV 
HLA-B*52:01 Concordant 2.67 1.63-4.37 9.4x10-5 0.03 
HLA-C*12:02 Concordant 2.31 1.41-3.75 0.0008 0.01 
HLA-DQA1*01:03 Concordant 1.75 1.24-2.45 0.0013 0.66 
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Table 4 Frequency of NAT2 alleles in case and controls of European and Indian cohorts  
 



















NAT2*4 0.23 0.24 0.29 0.14 1.06 0.71-
1.58 
0.75 0.22 0.16 0.66 0.39-
1.11 
0.12 N/P 0.77 0.61-
0.98 
0.81 0.1 
NAT2*5 0.46 0.37 0.34 0.41 0.7 0.49-
0.98 
0.04 0.33 0.25 0.68 0.43-
1.07 
0.1 C 0.69 0.57-
0.83 
0.01 0.43 
NAT2*6 0.29 0.35 0.31 0.41 1.3 0.91-
1.85 
0.14 0.37 0.5 1.77 1.18-
2.65 
0.01 C 1.42 0.97-
2.08 
0.03 0.05 
NAT2*7 0.02 0.04 0.04 0.04 1.88 0.81-
4.34 
0.14 0.08 0.08 1.09 0.55-
2.17 




Freq=allele frequency; INH=Isoniazid; INH comb = INH combination; P=multinomial p value; OR= odds ratio of a multivariate regression 
model correcting for population stratification; Pm =meta-analysis p value; HetP= Heterogeneity p value. Effect dir=effect direction; 
N/P=null/positive; C=concordant 
   
 28 
Table 5 Frequency of NAT2 acetylator status genotypes in European and Indian case/control cohorts and their association in a 
multivariate regression model 
 











OR 95%CI P Effect 
dir 
OR 95% CI Pm Het P 
Rapid 0.05 0.06 1.18 0.44-3.28 0.73 0.06 0.02 0.29 0.03-2.20 0.23 D 0.38 0.22-0.65 0.1 0.75 
Intermediate 0.35 0.36 1.02 0.62-1.66 0.93 0.34 0.29 0.8 0.43-1.45 0.45 D 0.9 0.64-1.26 0.95 0.21 
Slow 0.49 0.4 0.6 0.41-1.08 0.1 0.41 0.4 0.93 0.53-1.64 0.82 C 0.68 0.52-0.88 0.87 0.46 
Ultra Slow 0.1 0.19 2.03 1.10-3.72 0.02 0.19 0.29 1.78 0.98-3.39 0.06 C 1.89 0.84-4.22 0.004 0.3 
 
 
We considered (a) in rapid group *4/*4 genotypes; (b) in intermediate group *4/*5,*4/*6,*4/*7 genotypes; (c) in slow group *5/*5,*5/*6,*5/*7 
genotypes; (d) in ultra slow *6/*6,*7/*6,*7/*7 genotypes. 
Freq=allele frequency; P=multinomial p value; OR= odds ratio of a multivariate regression model correcting for population stratification; Pm 




Figure 1 Schematic summary of the study including details on the number of cases 
and controls and analysis steps undertaken. 
 
Figure 2 Manhattan plots displaying the association results of the genetic association 
analyses. (A) Manhattan plot showing the summary statistics for the European GWAS; 
(B) Manhattan plot showing the summary statistics for the Indian GWAS (C) 
Manhattan plot showing the summary statistics for the meta analysis. The overall 














Genome-wide genotyping on 70 
European anti-TB DILI cases & 10397 
population controls
Genome-wide genotyping of 55 
Indian anti-TB DILI cases & 1199 
Indian controls
After imputation of additional SNPs, assess association of individual SNPs with DILI 
by logistic regression, using additive model and adjusting for population structure. 
Perform separately in both cohorts followed by meta analysis.
Impute HLA genotypes from genome-wide genotyping data for cases and controls. 217 
alleles were imputed in Europeans and 192 in Indians. Assess association of individual 
alleles with DILI. Set p for significance at less than 2.5x10-4. Perform separately in both 
cohorts followed by meta analysis. 
Extract NAT2 genotypes from imputed GWAS data. Assess association of individual 
SNPs and acetylator genotypes with DILI in cases and controls. Perform separately in 
both cohorts followed by meta analysis.
Extract individual SNPs in additional candidate genes from imputed GWAS data. 
Assess association of SNPs individually with DILI in cases and controls. Set 
significance of p< 0.003 for 16 multiple comparisons. Perform separately in both 
cohorts.
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